top of page

NuvOx Pharma Receives FDA Allowance to Proceed with Phase II Clinical Trial of NanO2TM

Tucson, AZ, July 29, 2021 --(PR.com)-- NuvOx Pharma, a Tucson-based biopharmaceutical company, has received notice from the FDA that they may proceed with a Phase II clinical trial of their drug, NanO2TM, in ischemic stroke.

Recent Posts

See All

NuvOx Pharma Announces Issuance of a New Patent

Tucson, AZ,  January 2, 2024 - NuvOx Pharma has been issued US Patent No. 11,857,627, entitled “Fractionated Radiotherapy and Chemotherapy with an Oxygen Therapeutic.” Evan Unger, MD, President and CE

NuvOx Announces Contract to Support NOVEL Trial

Tucson, AZ, USA, October 31, 2023 - NuvOx Pharma (NuvOx), a clinical stage biotechnology company developing a first-in-class therapeutic to treat life-threatening diseases where hypoxia plays a role,

Comments


bottom of page